Htg Molecular Diagnostics Stock Fundamentals
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
HTG Molecular Diagnostics fundamentals help investors to digest information that contributes to HTG Molecular's financial success or failures. It also enables traders to predict the movement of HTG Stock. The fundamental analysis module provides a way to measure HTG Molecular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HTG Molecular stock.
HTG |
HTG Molecular Diagnostics Company Operating Margin Analysis
HTG Molecular's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current HTG Molecular Operating Margin | (3.15) % |
Most of HTG Molecular's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HTG Molecular Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, HTG Molecular Diagnostics has an Operating Margin of -3.1521%. This is 91.01% lower than that of the Health Care Technology sector and 95.03% lower than that of the Health Care industry. The operating margin for all United States stocks is 42.79% lower than that of the firm.
HTG Molecular Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HTG Molecular's current stock value. Our valuation model uses many indicators to compare HTG Molecular value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HTG Molecular competition to find correlations between indicators driving HTG Molecular's intrinsic value. More Info.HTG Molecular Diagnostics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value HTG Molecular by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.HTG Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HTG Molecular's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HTG Molecular could also be used in its relative valuation, which is a method of valuing HTG Molecular by comparing valuation metrics of similar companies.HTG Molecular is currently under evaluation in operating margin category among its peers.
HTG Fundamentals
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 6.37 M | |||
| Gross Profit | (2.01 M) | |||
| EBITDA | (20.14 M) | |||
| Net Income | (21.59 M) | |||
| Cash And Equivalents | 14.1 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 4.83 M | |||
| Debt To Equity | 2.52 % | |||
| Current Ratio | 1.90 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (18.41 M) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | (17.10) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 53 | |||
| Beta | 0.99 | |||
| Market Capitalization | 1.06 M | |||
| Total Asset | 17.78 M | |||
| Retained Earnings | (229.93 M) | |||
| Working Capital | 7.38 M | |||
| Current Asset | 34.86 M | |||
| Current Liabilities | 6.32 M | |||
| Z Score | -20.86 | |||
| Net Asset | 17.78 M |
About HTG Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HTG Molecular Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HTG Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HTG Molecular Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. Htg Molecular operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |